Skip to main content

Table 1 Baseline characteristics of the participants

From: A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis

Characteristic

TLHS 4.8 g

TLHS 3.6 g

TLHS 2.4 g

Placebo

Age, years, mean ± SD

47.54 ± 11.14

50.76 ± 9.69

50.59 ± 10.61

50.12 ± 10.45

Gender, n, M : F

12:47

11:48

8:51

7:52

Height, cm, mean ± SD

162.88 ± 6.49

162.08 ± 6.16

161.78 ± 5.40

162.37 ± 5.60

Weight, kg, mean ± SD

61.83 ± 9.87

61.04 ± 9.65

60.14 ± 9.04

61.88 ± 9.29

Marital status, married : other

53:6

56:3

55:4

56:3

Duration of disease, months

3.00–180.00

2.00–216.00

5.00–183.00

2.00–276.00

Medication, use : no use

20:39

28:31

32:27

28:31

Radiographic stage, I : II : III

30:25:4

23:32:4

27:22:10*

33:21:5

Joint functional stage, I : II : III

13:46:0

9:47:3

9:42:8

15:40:4

Pain (VAS), cm, mean ± SD

5.68 ± 1.12

5.68 ± 1.27

5.48 ± 1.19

5.52 ± 1.13

Tender joint counts, n, mean ± SD

9.12 ± 5.07

8.47 ± 5.06

7.36 ± 3.87

9.24 ± 5.33

Swollen joint counts, n, mean ± SD

6.27 ± 3.47

5.83 ± 3.34

5.20 ± 2.54

6.19 ± 3.57

Morning stiffness, min, mean ± SD

82.03 ± 37.73

81.36 ± 37.61

83.31 ± 50.88

90.25 ± 71.24

Grip strength, mmHg, mean ± SD

36.11 ± 25.84

32.53 ± 22.57

35.07 ± 24.00

34.87 ± 24.97

Physician’s assessments, score, mean ± SD

5.32 ± 1.12

5.34 ± 1.33

5.07 ± 1.11

5.30 ± 1.17

HAQ, score, mean ± SD

16.68 ± 11.87

18.10 ± 12.78

15.39 ± 11.09

17.07 ± 12.85

RF, U/ml, mean ± SD

163.69 ± 258.04

74.72 ± 110.88

99.19 ± 149.96

79.04 ± 131.09

CRP, mg/dl, mean ± SD

7.38 ± 15.13

11.11 ± 30.01

6.83 ± 12.42

7.49 ± 16.67

ESR, mm/h, mean ± SD

22.39 ± 19.73

27.21 ± 25.14

27.93 ± 25.00

26.39 ± 23.04

  1. *P < 0.05 versus the placebo group
  2. VAS visual analog scale, HAQ Health Assessment Questionnaire, RF rheumatoid factor, CRP C-reactive protein, ESR erythrocyte sedimentation rate